Please login to order a test.
Inheritest® Carrier Screen, Ashkenazi Jewish Panel (48 Genes)
- Extended Carrier Screening
- Pan-ethnic Carrier Screening
Screening for 48 genes, including fragile X carrier screening and spinal muscular atrophy (SMA) carrier screening. This test includes: ABCC8, ADAMTS2, AGL, ARSA, ASPA, ATM, ATP7B, BBS2, BCKDHA, BCKDHB, BLM, CFTR, CLRN1, COL4A3, CPT2, CTNS, DHCR7, DHDDS, DLD, FAH, FANCC, FKTN, FMR1, G6PC, GALT, GBA, HBA1, HBA2, HBB, HEXA, IKBKAP, MCOLN1, MEFV, MPL, MTTP, NEB, PAH, PCDH15, PEX2, PHGDH, PKHD1, PEX6, PMM2, SMPD1, TMEM216, SLC35A3, SMN1 and SUMF1.
Carrier screening by analyzing 48 genes for more than 2,300 pathogenic variants associated with more than 47 autosomal recessive or X-linked disorders including genes for fragile X syndrome, spinal muscular atrophy, and diseases specific to individuals of Ashkenazi Jewish descent.
Technologies used do not detect germline mosaicism and do not rule out the presence of large chromosomal aberrations, including rearrangements, or variants in regions or genes not included in this test, or possible inter/intragenic interactions between variants. Variant classification and/or interpretation may change over time if more information becomes available. False positive or false negative results may occur for reasons that include: rare genetic variants, sex chromosome abnormalities, pseudogene interference, blood transfusions, bone marrow transplantation, somatic or tissue-specific mosaicism, mislabeled samples, or erroneous representation of family relationships.
This test was developed and its performance characteristics determined by Esoterix Genetic Laboratories LLC. It has not been cleared or approved by the Food and Drug Administration.
Next generation sequencing (NGS): Genomic regions of interest are selected using the Agilent®SureSelectXT® hybridization capture method for target enrichment and sequenced via the Illumina® next generation sequencing platform. Sequencing reads are aligned with the human genome reference GRCh37/hg19 build. Targeted regions are sequenced to at least 200X mean base coverage with a minimum of 99% of bases at ≥20X coverage. Analytical sensitivity is estimated to be >99% for single nucleotide variants and small insertions/deletions (<5 bp).
Alpha‐thalassemia: Analysis of the alpha‐globin (HBA) gene cluster is performed by multiplex ligationdependent amplification (MLPA). Variants included in the analysis are the Constant Spring non‐deletion variant and the following deletions: ‐alpha3.7, ‐alpha4.2, ‐alpha20.5, ‐‐SEA, ‐‐FIL, ‐‐THAI, ‐‐MED, and the HS‐40 regulatory region. This MLPA analysis does not detect other variants in the alpha‐globin genes or variants in the beta‐globin gene and may not detect the co‐occurrence of a deletion and a duplication. Analytical sensitivity is estimated to be >99% for the targeted variants.
Spinal muscular atrophy: DNA is amplified by real‐time polymerase chain reaction (PCR). The number of copies of exon 7 of SMN1 is assessed relative to internal standard reference genes. A mathematical algorithm calculates 0, 1, 2 and 3 copies with statistical confidence. If one copy of SMN1 is detected, primer and probe binding sites are sequenced to rule out variants that could interfere with copy number analysis. If no copies of SMN1 are detected, SMN2 copy number is assessed by digital PCR analysis relative to an internal standard reference gene. Copy number analysis cannot detect carriers with either 2 or, very rarely, 3 copies of SMN1 on one chromosome and no copies of SMN1 on the other chromosome.
Fragile X syndrome: DNA is amplified by the polymerase chain reaction (PCR) to determine the size of the CGG repeat within the FMR1 gene. PCR products are generated using a fluorescence labeled primer and sized by capillary gel electrophoresis. If indicated, Southern blot analysis is performed by hybridizing the probe StB12.3 to EcoRI‐ and EagI‐digested DNA. The analytical sensitivity of both Southern blot and PCR analyses is 99% for expansion mutations in the FMR1 gene. Reported CGG repeat sizes may vary as follows: +/‐ one for repeats less than 60, and +/‐ two to four for repeats in the 60 ‐ 120 range. For repeats greater than 120, the accuracy is +/‐ 10%.
Pathogenic and likely pathogenic variants are reported after confirmation by Sanger sequencing or an appropriate technology. Non‐deletion variants are specified using the numbering and nomenclature recommended by the Human Genome Variation Society (HGVS, http://www.hgvs.org). Variants of uncertain significance and benign variants are not reported. Variant classification is consistent with ACMG standards and guidelines.1 Detailed variant classification information is available upon request.
Yellow-top (ACD-A) tube (preferred) or lavender-top (EDTA) tube; yellow-top (ACD-B) tube is not acceptable
Maintain specimen at room temperature or refrigerate at 4°C.
Causes for Rejection
Frozen specimen; hemolysis; quantity not sufficient for analysis; improper container; blood specimens more than four days post draw
Test orders must include an attestation that the provider has the patient's informed consent for genetic testing. See sample physician office consent form: Consent for Genetic Testing. Call Integrated Genetics at 855-422-2557 to obtain access to genetic counseling.
- 1. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424.25741868
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|451920||Inheritest-Ashkenazi Jewish||451999||Genetic Counselor: NGS Inheri||N/A|
|451920||Inheritest-Ashkenazi Jewish||451997||Specimen Type: InheriTest||31208-2|
|451920||Inheritest-Ashkenazi Jewish||451998||Ethnicity: InheriTest||42784-9|
|451920||Inheritest-Ashkenazi Jewish||451842||Ashkenazi Jewish Results:||53039-4|
|451920||Inheritest-Ashkenazi Jewish||451613||General Comments:||N/A|
|451920||Inheritest-Ashkenazi Jewish||451616||Additional Clinical Info||55752-0|
|451920||Inheritest-Ashkenazi Jewish||451614||Information Table||36908-2|
|451920||Inheritest-Ashkenazi Jewish||451612||Director Review:||72486-4|